-
公开(公告)号：HRP20210501T1
公开(公告)日：2021-05-14
申请号：HRP20210501
申请日：2021-03-29
Applicant: ARRAY BIOPHARMA INC , CELGENE CORP
Inventor： ALLEN SHELLEY , BOYS MARK LAURENCE , CHICARELLI MARK J , FELL JAY BRADFORD , FISCHER JOHN P , GAUDINO JOHN , HICKEN ERIK JAMES , HINKLIN RONALD JAY , KRASER CHRISTOPHER F , LAIRD ELLEN , ROBINSON JOHN E , TANG TONY P , BURGESS LAURENCE E , RIEGER ROBERT ANDREW , PHENEGER JED , SATOH YOSHITAKA , LEFTHERIS KATERINA , RAHEJA RAJ K , BENNETT BRYDON L
IPC: C07D487/04 , A61K31/4985 , A61P29/00 , A61P37/00
-
公开(公告)号：PH12020550622A1
公开(公告)日：2021-01-25
申请号：PH12020550622
申请日：2020-05-13
Applicant: MIRATI THERAPEUTICS INC , ARRAY BIOPHARMA INC
Inventor： BLAKE JAMES F , BURGESS LAURENCE E , CHICARELLI MARK JOSEPH , CHRISTENSEN JAMES GAIL , COOK ADAM , FELL JAY BRADFORD , FISCHER JOHN P , MARX MATTHEW ARNOLD , MEJIA MACEDONIO J , SAVECHENKOV PAVEL , VIGERS GUY P A , SMITH CHRISTOPHER RONALD , RODRIGUEZ MARTHA E
IPC: C07D401/14 , C07D401/06
Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
-
公开(公告)号：CA2771484C
公开(公告)日：2019-01-15
申请号：CA2771484
申请日：2010-08-18
Applicant: VENTIRX PHARMACEUTICALS INC , ARRAY BIOPHARMA INC
Inventor： HOWBERT JAMES JEFFRY , DIETSCH GREGORY , HERSHBERG ROBERT , BURGESS LAURENCE E , DOHERTY GEORGE A , EARY C TODD , GRONEBERG ROBERT D , JONES ZACHARY
IPC: C07D403/10 , A61K31/4025 , A61K31/55 , A61P31/00 , A61P35/00 , C07D223/14 , C07D401/14 , C07D403/14
Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll- like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease. The provided compositions include (see above formula)
-
公开(公告)号：AU2017266911A1
公开(公告)日：2018-12-06
申请号：AU2017266911
申请日：2017-05-17
Applicant: ARRAY BIOPHARMA INC , MIRATI THERAPEUTICS INC
Inventor： FISCHER JOHN P , FELL JAY BRADFORD , BLAKE JAMES F , HINKLIN RONALD JAY , MEJIA MACEDONIO J , HICKEN ERIK JAMES , CHICARELLI MARK JOSEPH , GAUDINO JOHN J , VIGERS GUY P A , BURGESS LAURENCE E , MARX MATTHEW ARNOLD , CHRISTENSEN JAMES GAIL , LEE MATTHEW RANDOLF , SAVECHENKOV PAVEL , ZECCA HENRY J , TANG TONY P
IPC: C07D231/56 , A61K31/445 , C07D295/185
Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
-
公开(公告)号：PL2467377T3
公开(公告)日：2017-10-31
申请号：PL10810563
申请日：2010-08-18
Applicant: VENTIRX PHARMACEUTICALS INC , ARRAY BIOPHARMA INC
Inventor： HOWBERT JAMES JEFFRY , DIETSCH GREGORY , HERSHBERG ROBERT , BURGESS LAURENCE E , LYSSIKATOS JOSEPH P , NEWHOUSE BRAD , YANG HONG WOON
IPC: C07D401/14 , A61K31/4025 , A61K31/454 , A61K31/55 , A61P31/00 , A61P35/00 , C07D223/14 , C07D403/10
-
Patent Agency Ranking
公开(公告)号：HUE032638T2
公开(公告)日：2017-10-30
申请号：HUE12733896
申请日：2012-01-12
Applicant: VENTIRX PHARMACEUTICALS INC , ARRAY BIOPHARMA INC
-
公开(公告)号：CO2017006674A2
公开(公告)日：2017-10-20
申请号：CO2017006674
申请日：2017-06-30
Applicant: CELGENE CORP , ARRAY BIOPHARMA INC
Inventor： BOYS MARK LAURENCE , BURGESS LAURENCE E , HICKEN ERIK JAMES , KRASER CHRISTOPHER F , LAIRD ELLEN , ROBINSON JOHN E , GAUDINO JOHN , ALLEN SHELLEY , CHICARELLI MARK J , RIEGER ROBERT ANDREW , PHENEGER JED , FELL JAY BRADFORD , FISCHER JOHN P , HINKLIN RONALD JAY , TANG TONY P , SATOH YOSHITAKA , LEFTHERIS KATERINA , RAHEJA RAJ K , BENNETT BRYDON L
IPC: C07D487/04 , A61K31/4985 , A61P29/00 , A61P37/00
Abstract: PIRAZOLO[1,5-A]PIRAZINAS 4,6-SUSTITUIDAS COMO INHIBIDORES DE JANUS CINASAS RESUMEN – OBJETO Y FINALIDAD DE LA INVENCIÓN Compuestos de Fórmula I: y estereoisómeros y sales solvatos farmacéuticamente aceptables de estos en los que R1, R2, R3 y R4 tienen los significados dados en la memoria descriptiva, son inhibidores de una o más JAK cinasas y son útiles en el tratamiento de enfermedades y trastornos relacionados con la JAK cinasa, tales como enfermedades autoinmunitarias, rechazo del trasplante de órganos¬, tejidos y células, así como también neoplasias y trastornos hematológicos y sus comorbilidades. Sector: Ciencias médicas y farmacéuticas
-
公开(公告)号：PL2663555T3
公开(公告)日：2017-08-31
申请号：PL12733896
申请日：2012-01-12
Applicant: VENTIRX PHARMACEUTICALS INC , ARRAY BIOPHARMA INC
Inventor： HOWBERT JAMES JEFFRY , HERSHBERG ROBERT , BURGESS LAURENCE E , DOHERTY GEORGE A , EARY CHARLES TODD , GRONEBERG ROBERT D , JONES ZACHARY , LYSSIKATOS JOSEPH P , YANG HONG WOON
IPC: A61K31/55 , A61P37/00 , C07D223/16 , C07D243/14 , C07D401/12 , C07D487/04
-
公开(公告)号：PL2663550T3
公开(公告)日：2017-07-31
申请号：PL12734770
申请日：2012-01-12
Applicant: VENTIRX PHARMACEUTICALS INC , ARRAY BIOPHARMA INC
Inventor： HOWBERT JAMES JEFFRY , HERSHBERG ROBERT , BURGESS LAURENCE E , YANG HONG WOON
IPC: C07D223/16 , A61K31/55 , A61P29/00 , A61P35/00 , C07D401/04 , C07D403/10 , C07D413/10 , C07D487/04
-
公开(公告)号：SG11201704542SA
公开(公告)日：2017-07-28
申请号：SG11201704542S
申请日：2015-12-04
Applicant: ARRAY BIOPHARMA INC , CELGENE CORP
Inventor： ALLEN SHELLEY , BOYS MARK LAURENCE , CHICARELLI MARK J , FELL JAY BRADFORD , FISCHER JOHN P , GAUDINO JOHN , HICKEN ERIK JAMES , HINKLIN RONALD JAY , KRASER CHRISTOPHER F , LAIRD ELLEN , ROBINSON JOHN E , TANG TONY P , BURGESS LAURENCE E , RIEGER ROBERT ANDREW , PHENEGER JED , SATOH YOSHITAKA , LEFTHERIS KATERINA , RAHEJA RAJ K , BENNETT BRYDON L
IPC: A61K31/4985 , C07D487/04 , A61P29/00 , A61P37/00
Abstract: Compounds of Formula I:and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R 1 , R 2 , R 3 and R 4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
-
-
-
-
-
-
-
-
-
Search Results
141
records
(took 0.03 seconds)
